ArticleCureus2026
Dapsone Toxicity in Relapsing Polychondritis: Methemoglobinemia and Concomitant Hemolytic Anemia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapsing polychondritis (RP) is a rare immune-mediated disorder characterized by episodic inflammation of cartilage and other proteoglycan-rich tissues. Dapsone is sometimes used as a steroid-sparing agent in selected phenotypes, but its oxidative metabolites can cause clinically significant methemoglobinemia and hemolysis. We describe a 70-year-old man with auricular chondritis and biopsy-supported RP who developed progressive dyspnea and cyanosis after three months of dapsone 100 mg daily. Oxygen saturation remained low despite supplemental oxygen, while arterial oxygen tension was preserved, prompting co-oximetry that confirmed methemoglobinemia. He improved rapidly after methylene blue administration, and dapsone discontinuation prevented recurrence. During the same admission, anemia worsened with laboratory and smear features consistent with oxidant hemolysis and a negative direct antiglobulin test, improving after drug withdrawal. This case highlights the diagnostic value of the "saturation gap" and the need to actively consider dapsone-related dyshemoglobinemia and oxidant hemolysis in patients with refractory low pulse oximetry readings or worsening anemia while on therapy, enabling timely confirmation and prompt drug withdrawal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.